Humanised IgG1K monoclonal antibody against interferon beta ( DrugBank: Interferon beta )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 50 | 皮膚筋炎／多発性筋炎 | 8 |
50. 皮膚筋炎／多発性筋炎
臨床試験数 : 194 / 薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-004787-10-ES (EUCTR) | 04/05/2022 | 08/02/2022 | An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS =18 AND =80 WITH ACTIVE DERMATOMYOSITIS. | Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive name: Humanised IgG1K monoclonal antibody against interferon beta | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | United States;Hungary;Poland;Spain;Australia;Germany;Italy | ||
| 2 | EUCTR2021-004787-10-HU (EUCTR) | 07/03/2022 | 29/12/2021 | An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS =18 AND =80 WITH ACTIVE DERMATOMYOSITIS. | Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive name: Humanised IgG1K monoclonal antibody against interferon beta | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | United States;Hungary;Spain;Poland;Australia;Germany;Italy | ||
| 3 | EUCTR2021-004787-10-PL (EUCTR) | 31/01/2022 | 05/01/2022 | An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS =18 AND =80 WITH ACTIVE DERMATOMYOSITIS. | Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive name: Humanised IgG1K monoclonal antibody against interferon beta | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | United States;Hungary;Spain;Poland;Australia;Germany;Italy | ||
| 4 | EUCTR2020-004228-41-DE (EUCTR) | 28/07/2021 | 17/02/2021 | A placebo-controlled study to evaluate the efficacy, safety and tolerability of PF-06823859 in adult subjects with Dermatomyositis | A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive name: Humanised IgG1K monoclonal antibody against interferon beta | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 76 | Phase 2 | United States;Hungary;Spain;Poland;Germany;Italy | ||
| 5 | EUCTR2020-004228-41-HU (EUCTR) | 07/07/2021 | 26/03/2021 | A placebo-controlled study to evaluate the efficacy, safety and tolerability of PF-06823859 in adult subjects with Dermatomyositis | A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive name: Humanised IgG1K monoclonal antibody against interferon beta | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 76 | Phase 2 | United States;Hungary;Spain;Poland;Germany;Italy | ||
| 6 | EUCTR2020-004228-41-IT (EUCTR) | 15/06/2021 | 07/06/2021 | A placebo-controlled study to evaluate the efficacy, safety and tolerability of PF-06823859 in adult subjects with Dermatomyositis | A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS - - | Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: PF-06823859 Product Code: [PF-06823859] Other descriptive name: Humanised IgG1K monoclonal antibody against interferon beta | PFIZER INC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 76 | Phase 2 | United States;Hungary;Spain;Poland;Germany;Italy | ||
| 7 | EUCTR2020-004228-41-ES (EUCTR) | 28/05/2021 | 01/09/2021 | A placebo-controlled study to evaluate the efficacy, safety and tolerability of PF-06823859 in adult subjects with Dermatomyositis | A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive name: Humanised IgG1K monoclonal antibody against interferon beta | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 76 | Phase 2 | United States;Hungary;Poland;Spain;Germany;Italy | ||
| 8 | EUCTR2020-004228-41-PL (EUCTR) | 13/04/2021 | 08/03/2021 | A placebo-controlled study to evaluate the efficacy, safety and tolerability of PF-06823859 in adult subjects with Dermatomyositis | A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive name: Humanised IgG1K monoclonal antibody against interferon beta | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 76 | Phase 2 | United States;Hungary;Spain;Poland;Germany;Italy |